Prostate Cancer MRI Prognostic Integrator
Pre-treatment MRI features provide independent prognostic information beyond PSA, Gleason grade, and clinical stage in prostate cancer — yet most existing risk calculators don't integrate MRI findings, creating a gap between what imaging tells us and how treatment decisions are made.
Prostate Cancer MRI Prognostic Integrator
Pre-treatment MRI features provide independent prognostic information beyond PSA, Gleason grade, and clinical stage in prostate cancer — yet most existing risk calculators don't integrate MRI findings, creating a gap between what imaging tells us and how treatment decisions are made.
Build an integrated prostate cancer risk stratification tool that combines traditional clinical variables (PSA, Gleason/ISUP grade, clinical stage) with pre-treatment mpMRI features (PI-RADS score, lesion size, extracapsular extension, seminal vesicle involvement) to generate a composite risk estimate and treatment guidance summary. The tool would draw on the meta-analytic evidence base for MRI-based prognostication and be calibrated against published outcome data from the 40-study meta-analysis.
For each patient profile entered, the tool would output a structured summary: estimated risk of adverse pathology at prostatectomy, predicted likelihood of biochemical recurrence at 5 and 10 years, recommended treatment discussion pathways (active surveillance, focal therapy, radical prostatectomy, radiation), and links to relevant guideline statements from AUA, EAU, and NCCN. An educational module would explain each MRI feature to patients using annotated images and plain language.
Prostate cancer is the most common cancer in men in most countries, and risk stratification drives one of the most consequential treatment decisions a man will face — whether to pursue active surveillance, local treatment, or more aggressive management. MRI is already performed in most prostate cancer workups; a tool that properly integrates MRI findings into the risk calculation would close a real gap between imaging availability and its use in clinical decision-making.
Who Is This For?
Urologists and radiation oncologists counseling prostate cancer patients, patients preparing to discuss treatment options, and clinical researchers evaluating prostate cancer risk stratification models.
Skills & Tools Needed
- Clinical knowledge of prostate cancer staging, MRI features, and risk stratification
- Web development with calculation and decision logic
- Statistical modeling for calibration to outcome data
- Medical writing for clinician and patient-facing outputs
- UX design for clinical decision support tools
Feasibility
medium — The clinical content is evidence-based and well-defined; the main challenge is proper statistical calibration of the composite risk model and ensuring clinical validation before widespread use.
Inspired by: MRI Before Treatment Could Provide Prognostic Information in Prostate Cancer
